Track topics on Twitter Track topics that are important to you
Ocular Therapeutix says it received a Complete Response Letter (CRL) from the US Food and Drug Administration…
US ophthalmology specialist Ocular Therapeutix (Nasdaq: OCUL) today announced the appointment of Michael…
BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 11, 2017-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative thera...
Ocular Therapeutix failed for a second time to secure approval of its eye drug Dextenza. On Tuesday, the FDA rejected the drug.
NewsOcular Therapeutix receives complete response letter from FDA for Dextenza NDA. The company believes that approval will come once the open manufacturing items are resolved.
An experimental eye drug from Ocular Therapeutix, already rejected once by the FDA, could this month be turned away a second time because of product contamination, including aluminum, found by…
Biopharmaceutical company focused on the development, manufacture and commercialisation of therapies for ocular conditions, Ocular Therapeutix, has received a complete response letter regarding its r...
Ocular Therapeutix is still working to resolve manufacturing problems with its eye drug, less than two weeks before an FDA approval decision deadline.
Ocular Therapeutix, Inc.Â (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of t...
Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietar...
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its p...
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the ...
We have published hundreds of I-Therapeutix, Inc. news stories on BioPortfolio along with dozens of I-Therapeutix, Inc. Clinical Trials and PubMed Articles about I-Therapeutix, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of I-Therapeutix, Inc. Companies in our database. You can also find out about relevant I-Therapeutix, Inc. Drugs and Medications on this site too.